

BRAZILIAN MEETING ON ORGANIC SYNTHESIS BENTO GONCALVES, RS - BRAZIL

Iodine-catalyzed synthesis of pyrido/benzo[b][1,4]selenazines


Felipe B. Santos, Emily Pezzini, Roberta Cargnelutti, Filipe Penteado and Ricardo F. Schumacher* Department of Chemistry, Federal University of Santa Maria, UFSM, 97105-900, RS, Brazil *e-mail: ricardo.schumacher@ufsm.br

Keywords: lodine, β -dicarbonyl compounds, 1,4-selenazines.

ABSTRACT

The synthesis of selenium-functionalized heterocycles is of growing interest due to their widespread applications as synthetic intermediates, optoelectronic devices, and pharmacologically active compounds.¹ Among them, benzo[1,4]selenazines, bearing a selenium and a nitrogen atom organized in a six-membered ring fused to a benzene unit, found synthetically usefulness in the preparation of functional organic materials,² and in medicinal chemistry as multi-targeting drug to treat Alzheimer's disease and microbial infections.³

This work describes the selective synthesis of pyrido/benzo-fused 1.4-selenazines through the reaction of bis(3-amino-2-pyridyl) or bis(2-aminophenyl) diselenides 1 with various β -dicarbonyl compounds 2. When molecular I₂ was used as catalyst, a series of pyrido/benzo[b][1,4]selenazines **3** bearing an exocyclic α,β -unsaturated system with Z configuration were obtained (Scheme 1). The versatility of the protocol was demonstrated not only by the access to a variety of 1,4-selenazine derivatives, but also by the structural diversity in the 1,3-dicarbonyl precursors, incorporating multifunctionalities in the synthesized heterocycles.



Scheme 1. Synthesis of pyrido/benzo[1,4]selenazines.

ACKNOWLEDGEMENTS

The authors thank FAPERGS (ARD 23/2551-0000800-9) and CNPq. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001. RFS also thanks CNPq for the fellowship received.

REFERENCES

- (1) (a) Bartz, R. H.; Dapper, L. H.; Kazmierczak, J. C.; Schumacher, R. F.; Perin, G.; Thurow, S.; Penteado, F.; Lenardão, E. J. Catalysts 2023, 13, 520. (b) Hou, W.; Xu, H. J. Med. Chem. 2022, 65, 4436-4456. (c) Nogueira, C. W.; Barbosa, N. V.; Rocha, J. B. T. Arch. Toxicol. 2021, 95, 1179-1226.
- (2) Lee, D. R.; Lee, K. H.; Shao, W.; Kim, C. L.; Kim, J.; Lee, J. Y. Chem. Mater. 2020, 32, 2583-2592.
- (3) (a) Tin, G.; Mohamed, T.; Gondora, N.; Beazely, M. A.; Rao, P. P. N. MedChemComm 2015, 6, 1930. (b) Foley, J. W.; Song, X.; Demidova, T. N.; Jalil, F.; Jilal, F.; Hamblin, M. R. J. Med. Chem. 2006, 49, 5291-5299.